Deininger Kimberly M, Page Robert L, Lee Yee Ming, Kauffman Yardlee S, Johnson Samuel G, Oreschak Kris, Aquilante Christina L
Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, CO, USA.
Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, CO, USA.
Per Med. 2019 Mar;16(2):123-132. doi: 10.2217/pme-2018-0099. Epub 2018 Dec 13.
To evaluate factors influencing cardiologists' perspectives about pharmacogenomic (PGx) testing in clinical practice.
PATIENTS & METHODS: Semistructured interviews with practicing cardiologists were qualitatively analyzed to identify common themes.
Five themes were identified among 16 cardiologists from four specialties (n = 5 general cardiology, n = 3 electrophysiology, n = 2 adult congenital and n = 6 heart failure/transplant): cardiologists' knowledge and needs, perceived clinical validity and utility of PGx testing, dissemination and management of PGx results, patient-related considerations and incidental findings.
Lack of evidence was considered by many cardiologists to be a major barrier hindering the use of PGx testing. However, they would consider adopting PGx if they were provided additional education, ongoing support and evidence supporting the clinical utility of PGx testing in cardiovascular medicine.
评估影响心脏病专家对临床实践中药物基因组学（PGx）检测看法的因素。
对执业心脏病专家进行半结构化访谈，并进行定性分析以确定共同主题。
在来自四个专业的16位心脏病专家中确定了五个主题（n = 5名普通心脏病学专家，n = 3名电生理学专家，n = 2名成人先天性心脏病专家，n = 6名心力衰竭/移植专家）：心脏病专家的知识与需求、PGx检测的临床有效性和实用性、PGx结果的传播与管理、患者相关考虑因素及偶然发现。
许多心脏病专家认为缺乏证据是阻碍PGx检测应用的主要障碍。然而，如果能获得额外的教育、持续的支持以及支持PGx检测在心血管医学中临床实用性的证据，他们会考虑采用PGx检测。
Zotero 插件